Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 |
| clinicaltrials |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma(ReLive) | completed | Phase 3 | 397 | Valerio TherapeuticsINDUSTRY | 11 | Jun 2, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT01755767 | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy(METIV-HCC) | completed | Phase 3 | 383 | Daiichi SankyoINDUSTRY | 16 | Apr 6, 2021 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT01833299 | Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers(ABC06) | completed | Phase 3 | 162 | The Christie NHS Foundation TrustOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01229839 | Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC | completed | Phase 3 | 668 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01259414 | Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma | completed | Phase 3 | 812 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT03636620 | TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial(TACE+RFA) | completed | Phase 3 | 110 | Fudan UniversityOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT01829035 | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | completed | Phase 3 | 339 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT01804829 | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | completed | Phase 3 | 80 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01482442 | SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma(SARAH) | completed | Phase 3 | 496 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT02788526 | Adjuvant TACE to Reduce the HCC Recurrence After Resection | completed | Phase 3 | 180 | Sun Yat-sen UniversityOTHER | 1 | Jun 20, 2016 | clinicaltrials |
| NCT01964001 | The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer | completed | Phase 2 / Phase 3 | 71 | Taichung Veterans General HospitalOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT00769106 | Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer(HCC-CIK) | completed | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT01749865 | CIK Treatment for HCC Patient Underwent Radical Resection | completed | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00241020 | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 270 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 12, 2016 | clinicaltrials |
| NCT00814242 | Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels | completed | Phase 2 / Phase 3 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT01521702 | NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer(NEOPAC) | completed | Phase 3 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00355355 | A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 208 | Light Sciences OncologyINDUSTRY | 11 | Jan 30, 2015 | clinicaltrials |
| NCT00467974 | Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma | completed | Phase 3 | 98 | Chinese University of Hong KongOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00105443 | A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma(SHARP) | completed | Phase 3 | 602 | BayerINDUSTRY | 23 | Oct 31, 2014 | clinicaltrials |
| NCT00355862 | Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma | completed | Phase 3 | 525 | University of RegensburgOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT00492752 | A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 226 | BayerINDUSTRY | 3 | Apr 16, 2014 | clinicaltrials |
| NCT00869635 | S-1 and Photodynamic Therapy in Cholangiocarcinoma | completed | Phase 3 | 43 | Asan Medical CenterOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00494299 | Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) | completed | Phase 3 | 458 | BayerINDUSTRY | 2 | Dec 20, 2013 | clinicaltrials |
| NCT00357474 | Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs | completed | Phase 3 | 22 | Seoul National University HospitalOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00328770 | De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 70 | University of AlbertaOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00088894 | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 3 | 590 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00493402 | Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma(TACEforHCC) | completed | Phase 3 | 365 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT01717729 | Hepatocellular Carcinoma Treated With Iodine-125 Implantation | completed | Phase 3 | 136 | The Second People's Hospital of GuangDong ProvinceOTHER | 0 | Oct 30, 2012 | clinicaltrials |
| NCT01088581 | Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma | completed | Phase 3 | 101 | Yonsei UniversityOTHER | 1 | Feb 2, 2012 | clinicaltrials |
| NCT00471965 | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients(EACH) | completed | Phase 3 | 371 | SanofiINDUSTRY | 4 | Sep 20, 2010 | clinicaltrials |
| NCT00495846 | GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma(SS-HCC) | completed | Phase 2 / Phase 3 | 25 | Federico II UniversityOTHER | 1 | Aug 17, 2009 | clinicaltrials |
| NCT00652587 | Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma | completed | Phase 3 | 115 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Oct 18, 2022source: clinicaltrials